Belite Bio, Inc
tinlarebant
Stargardt disease type 1
Date
TBD
Approval decision · Date TBD estimated
What's at stake
A final FDA approval decision on tinlarebant for Stargardt disease type 1 is expected Date TBD.
Primary source
· SEC 6-K
verified 12h ago
“Belite Bio plans to file a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) in 1H 2026”